P atients with chronic, life-limiting illnesses face serious and confusing healthcare decisions in the last years of life that documents such as living wills often complicate. [1] [2] [3] A preferred approach involves legally appointing a healthcare agent or proxy, 4 but most efforts to prepare surrogates to make substituted decisions have been unsuccessful. A systematic review of the accuracy of surrogate decisionmaking 5 concluded that surrogates incorrectly predicted patients' treatment preferences in one-third of cases. Of the 16 articles reviewed, only two used an intervention intended to improve surrogate understanding of patient preferences. 6, 7 Neither of these two articles showed significant improvement in surrogate understanding of patient choices in their intervention groups.
Three recent pilot studies provide evidence that structured advance care planning (ACP) interventions to prepare patients and their surrogates to understand expected complications, make informed decisions before a medical crisis, and communicate patient goals may reduce conflict, relieve the family of the decision-making burden, and ensure that patient goals for care are known and honored. 8 A randomized study of 61 geriatric patients, 9 in which the intervention group participate in a discussion facilitated using Respecting Choices (a program that teaches professionals how to obtain advance directives), 10 and two pilot studies that, like the current study, tested the Patient-Centered Advance Care Planning (PC-ACP) intervention, showed 11 ,12 a significant increase in surrogate understanding of patient preferences (P 5.01). The intervention was recently used with adolescents living with human immunodeficiency virus infection and their families, and researchers found greater congruence, less patient decisional conflict, and better quality of communication. 13 Little other research has been conducted concerning the effectiveness of interventions promoting ACP and advance directives (ADs). 14 The current study reports the results of a larger, randomized controlled trial examining the effect of PC-ACP on surrogate understanding of patient goals for future medical care, patient and surrogate knowledge of ACP, and intervention patient and surrogate evaluation of the quality of communication regarding the structured interview. It was hypothesized that a facilitated disease-specific planning discussion that included the surrogate decision-maker would favorably affect the surrogate decision-maker's understanding of the patient's wishes and the patient's and surrogate's knowledge about ACP.
METHODS

Design and Setting
The study used a randomized controlled design. Patients with congestive heart failure (CHF) or end-stage renal disease (ESRD) and their surrogates were randomized to receive the PC-ACP intervention (intervention group) or usual care (control group) using the sealed-envelope method within each setting and disease condition. The project director generated the allocation sequence using a computerized random number generator. The study was conducted in a similar fashion at medical centers headquartered in La Crosse and Madison, Wisconsin. The La Crosse center recruited patients with CHF from an outpatient, multispecialty clinic and patients with ESRD from two nephrology clinics and dialysis units. The Madison center recruited patients with CHF from a cardiac rehabilitation clinic and from CHF clinics located in Madison and Milwaukee; patients with ESRD were recruited from two dialysis clinics. La Crosse has a long history of community-level ACP education, in contrast to the Madison center and sites, where no such organized community-level ACP education has taken place. The Health Sciences Institutional Review Board and Human Subjects Committee of the University of Wisconsin-Madison and of Gundersen Clinic, Ltd. and the institutional review board of all the cooperating sites approved the study. It was registered at clinicaltrials.gov.
Participants
Patients and their designated surrogate decision-makers were recruited as pairs. Patients with CHF and ESRD were chosen because these patient populations present similarities and differences at the end of life. Individuals with both diagnoses have a chronic illness with a steady decline marked by exacerbations and incomplete recovery. Both groups are at high risk for sudden complications that may cause them to lose decision-making capacity and leave an unprepared surrogate. In addition, patients with ESRD have the possibility of discontinuing a single technology supporting their life, which could result in a short end-oflife period. The selection of patients focused primarily on those who were receiving medical care but had clinical symptoms and signs that indicated a risk of serious complication or death in the next 2 years. Patients with CHF had a New York Heart Association classification of II, III, or IV. Patients with ESRD had a serum albumin concentration less than 3.7 g/dL and a comorbidity such as diabetes mellitus, CHF, chronic obstructive pulmonary disease, a history of acute myocardial infarction, or an above-the-knee amputation. Patients chose their surrogates, who agreed to make healthcare decisions should the patient become unable. Participants were aged 18 and older, had decisionmaking capacity, and were able to speak and understand English. Decision-making capacity was determined by choosing patients who did not have an activated power of attorney for healthcare and through consultation with the clinicians providing care to the patients. Patients were referred to the clinic social worker for assistance in completing a durable power of attorney for health care if they did not have one or if they wished to update their current one.
Screening and Enrollment
Inservices were held to train clinic staff to screen participants. Clinic staff were given inclusion criteria and reviewed the medical records of patients scheduled for appointments to determine eligibility. Research staff met weekly with clinic staff to answer questions and ensure that all eligible patients were approached. Because of Health Insurance Portability and Accountability Act and clinic rules, investigators could neither screen nor directly approach eligible patients. Clinical staff asked eligible patients whether they were interested in more information about the study. If a patient was interested, a member of the research staff explained the study, determined whether the patient had a surrogate decision-maker, obtained informed consent, and enrolled the patient. If the surrogate was not present at that time, an appointment was made with the patient and surrogate for data collection.
Power Analysis
The projected sample size per treatment group was based on pilot data 11 and previous research findings establishing a range of baseline congruence values (35-70% agreement). 15, 16 The lower agreement figure of 35% was used in the power calculation, with the assumption that the value was constant. A moderate treatment effect of 71% increase in agreement (35% baseline increased to 60% postintervention) was assumed. Therefore, a total sample of approximately 560 patient-surrogate pairs evenly divided between the intervention group and the control group would be required to maintain a 0. 
Data Collection
All participants completed the measures on paper unless they had literacy or vision problems that precluded reading the forms. Any participants who expressed inability to read or who asked for assistance were offered the option of having the research assistant read the questions and answers aloud. Approximately 25% of the patients and no surrogates had the questions read to them. All patients and surrogates completed all measures separately. If they required assistance completing the forms, this was done in separate rooms. The research assistant assigned patientsurrogate pairs to the control group or an intervention group based on the sealed envelope method. Control pairs completed initial outcome measures upon entry into the study. Intervention pairs received the PC-ACP interview and completed outcome measures immediately afterward. Because of the nature of the intervention, the PC-ACP facilitator was not blinded to group assignment.
Usual Care
All patients received care provided by their local health organization for the completion of ADs. For the La Crosse center, usual care includes ACP facilitation with the patient but not the in-depth, patient-centered intervention in the presence of the surrogate decision-maker that is described in this study. For all sites, usual care included standard AD counseling, assessment of an AD on admission to the organization, and questions as to whether they would like more information. If they desired assistance, they were referred according to institutional protocol.
Intervention
The intervention was derived from previous work 10, 17 and consisted of the PC-ACP structured interview delivered by a trained facilitator that resulted in documentation of patient goals for care in the medical record using a disease-specific Statement of Treatment Preferences (STP) form. The PC-ACP interview included the patient and the surrogate decision-maker and lasted between 60 and 90 minutes. The purposes of the interview were to assess the patient's and the surrogate's understanding of the patient's illness, experiences, hopes, fears, and concerns; to provide individualized information about disease-specific treatment choices and their benefit and burdens; to assist in the documentation of disease-specific goals of care; and to prepare the surrogate to understand the patient's choices and make future decisions to honor these choices (http://www2.edc.org/lastacts/ archives/archivesmarch03/featureinn.asp). The first stage of the interview assesses the patient's understanding of the current medical condition, potential complications, hopes, fears, and perception of living well. The second stage of the interview explores experiences the patient may have had that have affected their goals for future medical decisionmaking. Stage three of the interview assists the patient and surrogate in appreciating the value of discussing specific treatment choices the patient is likely to experience in the future and how these discussions will prepare the surrogate to make substitute decisions based on a more-thorough understanding of the patients' goals and preferences. Stage four of the interview uses a disease-specific STP document to help the patient and surrogate understand real scenarios that may occur because of illness complications and to assist the patient in verbalizing goals and values related to acceptable and unacceptable burdens and outcomes. This document allows the facilitator to introduce replacement information, such as why the patient is at risk for certain complications and the benefits and burdens of a particular life-sustaining treatment (e.g., cardiopulmonary resuscitation). Surrogates are encouraged to ask questions to help them better understand patients' goals and to prepare for the types of decisions they may be asked to make if the patients cannot make their own decision. Stage five summarizes the value of the discussion for patients and surrogates, the need for future discussions as situations and preferences change, and the expectation that patients are more likely to have their wishes honored in the future. The representational approach to patient education theoretically supported the interview. 18 Further information about the intervention can be found elsewhere. 11 
PC-ACP Facilitator Training
The PC-ACP interview required professionals skilled in the content, techniques, and delivery of the intervention. A competency-based educational approach was used to train the six research staff (three nurses, two social workers, and a chaplain) who conducted the PC-ACP interviews. All interviewers successfully demonstrated predefined competencies after videotape review and individual feedback. One year after training, all facilitators were observed and given feedback. All demonstrated fidelity to the delivery of the PC-ACP interview and consistency at that time.
Instruments
Pre-Intervention Measures
Demographic Data Sheet (completed by patient and surrogate) included age, sex, race, marital status, education, and religious preference.
Outcome Measures
Knowledge about the ACP (completed by patient and surrogate) developed for this study assessed understanding of the purposes of an AD, ACP, and issues such as the role of the surrogate. This is a 10-item, true/false/don't know questionnaire. Included were questions about whether ADs allow the patient to make different choices in the future and under what circumstances the surrogate may be asked to become involved in decision-making. Higher scores indicated higher understanding of ACP. Two experts in ACP and one with expertise in psychometrics assisted with content validity of the instrument. Cronbach a values were 0.76 for patients and 0.79 for surrogates in one study of 32 pairs in which the patients had undergone open heart surgery.
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STP (completed by patient and surrogate separately) 17 serves as a decision aid and documentation tool to promote understanding of likely situations that could occur in the future and to express the patients' goals of treatment in terms of acceptable and unacceptable burdens and outcomes. The first three situations in the STP described an outcome from a complication of the patient's illness after a trial of treatment was provided: (Situation 1) a prolonged hospital stay requiring ongoing medical interventions and with a low chance of survival (e.g., o5%); (Situation 2) a good chance of survival, with permanent, severe functional impairment (could not walk, talk) requiring 24-hour nursing care; and (Situation 3) a good chance of survival, with permanent, severe cognitive impairment (did not know who I was or who I was with) requiring 24-hour nursing care. For each situation, after discussion and clarification of the meaning of the situation, patients were asked to choose one of three options: continue all treatment, stop all treatment to prolong my life, or don't know. Situation 4 described a sudden event causing the patient's heart and breathing to stop in which the chance of recovery may be low and the burdens of treatment may be high, and the choices were do not attempt resuscitation, attempt resuscitation, or do not attempt resuscitation if the treating physician believes the chance of survival is low. An additional item, a latitude statement, clarified the decision-making authority a patient wished to grant the chosen surrogate (patient's form) and the surrogate's understanding of that authority (surrogate's form). From the following three options, surrogates were asked to choose the one that best described their understanding of their decision-making authority: strictly follow the wishes, do what the surrogate thinks is best at the time, or don't know.
Quality of Patient-Clinician Communication About End-of-life Care (completed only by patients and surrogates in the intervention group) 19 consists of four items used to determine the quality of patient-facilitator communication about end-of-life care and a single generic rating question. Items are rated on a 3-point scale from no to definitely yes, with higher scores indicating higher satisfaction with the quality of communication. Good internal consistency has been reported in patients with acquired immune deficiency syndrome (Cronbach alpha 5 0.81). 20 In a pilot study, internal consistencies for patients and surrogates were 0.87 and 0.88, respectively. 10 This is reported only on the intervention group because the control group did not have conversations regarding future medical care with a PC-ACP facilitator.
Statistical Analysis
Chi-square and t-tests were used to compare demographic variables to ensure that the samples were comparable. Initially, kappa statistics were used to estimate surrogate understanding of patient choices for each scenario presented. Logistic regression was used to determine the relationship between the surrogate's choices and those of the patient. These logistic regression models were constructed for each situation using the patient's choices as the reference. The models were then expanded to assess possible interactions between treatment and select covariates of patient age, patient knowledge, patient educational level, site, surrogate educational level, and surrogate knowledge.
For the secondary outcome of knowledge of ACP, the Knowledge About ACP instruments were scored and the group scores compared using a Mann-Whitney U-test. The quality of communication instrument was used only in the intervention group to provide the participant's assessment of the ACP facilitation session.
RESULTS
Of 701 interested, eligible patients, 338 (48.2%) were enrolled. Reasons for interested, eligible patients not enrolling were not given consistently. Of the enrolled patients, 313 (92.6%) and their surrogates completed the study (Figure 1 ). Of those patients who were enrolled and did not complete the study, two (0.59% of enrolled) died or became too ill Analyzed n=64 Analyzed n=89
Intervention analyzed n=160
Control analyzed n=153
Analyzed n=70 Analyzed n=90 CHF Allocated to control n=104 Figure 1 . Flow of study participants. ESRD 5 end-stage renal disease; CHF 5 congestive heart failure.
before data could be collected, two (0.59%) could not identify a surrogate, 14 (4.1% of enrolled) surrogates decided not to participate, and seven (2.1% of enrolled) decided to withdraw with no further reason given. Although the power analysis indicated that 560 patientsurrogate pairs would be optimal, recruitment was halted with 313 pairs (55.9% of projected) at the end of the funding period because it was not feasible to continue.
Of those who completed the study, 179 had a diagnosis of end-stage CHF (La Crosse, n 5 134; Madison n 5 45), and 134 had ESRD (La Crosse, n 5 98; Madison, n 5 36). An intent-to-treat analysis was conducted.
Control (n 5 153) and intervention (n 5 160) patients had mean ages of 70 and 71, respectively (range 37-93), and were likely to be married, white, and Protestant (Table 1) . Surrogates were on the average younger, predominately female, married, and Protestant.
In all four expected outcome situations and in the latitude statement (amount of authority given to the surrogate), surrogates in the intervention group had significantly greater understanding of patient goals than those in the control group. Kappas ranged from 0.61 to 0.78 in the intervention group and 0.07 to 0.28 in the control group. The odds ratio for surrogate understanding of patient goals in the expected outcome situations ranged from 2.04 to 5.57 (Table 2) . For Situation 1, the patient hospitalized with a serious complication and a low chance of survival, education was related to the probability of surrogate understanding of patient preferences, with those of lower educational attainment ( high school education) having significantly greater surrogate understanding for the intervention group than the control group (Table 3, Figure 2 ). For Situation 4, cardiopulmonary resuscitation, surrogate knowledge of ACP had an effect on surrogate knowledge of patient preferences, with surrogates with less knowledge of ACP receiving more benefit from the intervention.
For Situation 5, the amount of latitude in decisionmaking that the patient wishes to give the surrogate, age was related to surrogate understanding, with older patients having greater surrogate understanding in the intervention group than the control group (Table 3, Figure 2 ).
Knowledge of ACP
Patients (mean 8.3 AE 2.1) and surrogates (mean 8.8 AE 1.7) in the intervention group had significantly (P 5.001) but only slightly higher scores in knowledge of ACP than the control patients (mean 7.5 AE 2.1) and surrogates (mean 8.2 AE 2.1).
Rating of Quality of Communication
The quality-of-communication tool has a 1 to 17 range. The mean intervention patient (n 5 156) score was 15.9 AE 1.5 and the mean surrogate (n 5 158) score was 16.1 AE 1.3.
The intervention group did not report any adverse effects. Some data were missing because participants did not respond.
DISCUSSION
A surrogate's understanding of a patient's informed choices for future medical care is critical for the surrogate to be able to make decisions that conform to the patient's goals of care. Surrogate understanding of patient goals is especially important for patients with chronic, life-limiting illnesses, when critical and complex medical decision-making can be expected for sudden, yet not surprising, complications. The common ACP approach to the completion of traditional ADs that is focused only on eliciting preferences for specific types of treatment modalities has been shown to be ineffective. 21 Although it seems intuitive that the surrogates would have greater understanding of the patient's goals after an hour-long ACP discussion, most previous studies have not shown an improvement of the surrogates' understanding of the patient's preferences after a planning process. 22 Those that have been effective have included elements that were incorporated into the PC-ACP interview. For example, recent research has indicated that interaction with a knowledgeable person, in this case the trained facilitator, and the opportunity to discuss individual concerns are critical to the effectiveness of ACP and AD interventions. 23 Another recognized element of effective interventions, incorporated into the PC-ACP intervention, is the need for identification and correction of patient misconceptions regarding the results of treatment. 24 This is the first large, multisite clinical trial that has shown a significant improvement in surrogate understanding of patient goals and preferences for future medical decisions. Such improved understanding is a necessary condition for better substituted decisions. Surrogate lack of understanding of patient preferences in the control group is of concern. For example, in the control group, most surrogates did not understand the degree of latitude granted by the patient to the surrogate concerning decision-making authority. Only 41.9% of the control surrogates knew the amount of latitude that the patient chose, compared with 82.6% in the intervention group. It has been found that patients often wish to give surrogates leeway in decisionmaking and do not always want surrogates to follow their choices strictly. 25 This intervention helped the surrogates to understand how the patient expected them to use known goals and preferences in decision-making. Such improvement of understanding in the intervention group was superior in the other four situations as well. Age, patient education, and surrogate knowledge of ACP had an effect on surrogate understanding of patient preferences. In Situation 1, less-educated patients in the intervention group demonstrated significantly greater improvement in surrogate understanding than those in the control group, as did less-knowledgeable surrogates and older patients in the intervention group in Situation 5. This might indicate that older and less-educated patients have a greater need for a facilitated and structured disease-specific planning discussion to improve surrogate understanding of patient goals for future medical care. It also suggests that this intervention might help address the problems of health literacy that may affect end-of-life choices. 26 Finally, the quality of communication findings provide evidence that patients and surrogates in the intervention group were highly satisfied with the quality of communication in the PC-ACP interview, dispelling fears that these types of conversations will cause harm by creating anxiety or taking away hope.
There are several potential limitations of this study. One important limitation was the requirement that patients have a surrogate decision-maker who could meet with the facilitator. Patients who did not have a surrogate decisionmaker and did not want to name one were not included. Patients who are not able to express their wishes directly and do not have a surrogate may express their wishes through a document such as a living will. Also, a number of patients agreed to participate but became too ill or died by the time an interview could be arranged with the surrogate. This group might have made different choices and had different conversations with their surrogates than those who were able to participate. In addition, the number of patients who might have been eligible but were not approached or refused to speak to research staff was not known. The participants were predominantly white, so the findings cannot be generalized to other racial and ethnic groups. An additional limitation was that the La Crosse participants were in an environment in which ACP is standard, which may have diminished the size of the effect of the intervention on them. 27 There might also be regional differences in other parts of the country to which these results might not apply; patients in this study were primarily from Wisconsin and cities bordering the state. For the purposes of this study, participants chose from among three options for each scenario presented. In real life, the situations are often not as clear, and the options available are different from those presented. For research purposes, such wide variation in preferences could not be captured, which might make a significant clinical difference. Finally, the achieved sample was only 55.9% of the projected sample needed in the power calculation. Although this smaller sample demonstrated statistically significant differences between the groups, a larger sample would be more compelling.
Patients with life-limiting illnesses and their families who struggle with complex treatment decisions would benefit from patient-centered, disease-specific planning. Although the STP used in this study focused on specific scenarios and limited outcomes, the facilitated discussion provided an opportunity for patients to express the values and beliefs that supported their choices. Surrogate knowledge of those underlying principles is an invaluable foundation for surrogate decision-making using substituted judgment. It can help prepare patients and their surrogates to better understand goals of care. This intervention shows that trained facilitators can assist patients with serious illness in understanding their treatment options and goals and making timely and proactive informed healthcare decisions and can prepare surrogates for future medical decisionmaking, increasing the likelihood that a patient's goals and preferences are communicated and honored when complex treatment choices are faced.
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